相关实验视频

Updated: Jan 16, 2026

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

使用自发报告数据库评估眼内抗血管内皮生长因子 (VEGF) 与药物相关的不良事件

Mugita Sato¹, Koichi Kageyama¹, Seiichiro Ito¹

¹Laboratory of Drug Informatics, Gifu Pharmaceutical University, Gifu, JPN.

|October 3, 2025

概括

抗血管内皮生长因子 (VEGF) 药物与罕见但严重的不良事件,如脑梗塞有关. 这项研究发现,若使用拉尼比祖马布 (IVR),脑梗塞可能比使用阿弗利伯塞普 (IVA) 早发生.

科学领域:

眼科医生眼科眼科
药物监督药物监督药物监督
神经学神经学

背景情况:

抗血管内皮生长因子 (VEGF) 药物是视网膜疾病的标准治疗方法,如黄斑.
虽然这些药物是有效的,但它们存在罕见但严重的不良事件的风险,例如脑梗塞.
调查这些风险对于患者安全至关重要.

研究的目的:

评估与抗VEGF药物相关的不良事件,特别是脑梗塞的风险和发病时间.
使用日本药物不良事件报告 (JADER) 数据库进行全面分析.

主要方法:

使用"监管活动医学词典" (MedDRA) 编码不良事件.
报告几率比率 (ROR) 被计算出来以评估事件频率.
使用生存分析,包括日志等级和通用威尔科克森测试,以确定发病时间.

主要成果:

分析了2004年4月至2025年1月965286份报告.
脑梗塞报告:阿弗利伯塞普特 (IVA) 200例,拉尼比祖马布 (IVR) 154例,布罗卢齐祖马布 (IVB) 16例,法里西马布 (IVF) 20例.
与IVA (79.0天) 相比,IVR (48.5天) 的中位时间到脑梗塞的发病时间明显较早.

结论:

与aflibercept (IVA) 相比,拉尼比祖马布 (IVR) 可能更早地表现出脑梗塞.
强调对抗VEGF治疗进行警监测的重要性.
强调在临床实践中需要个性化治疗策略.

关键词:

一个自由的接受.与年龄相关的黄斑变性.日本药物不良事件报告数据库数据库拉尼比祖马布拉尼尼比祖马布拉尼时间到发病分析分析.

更多相关视频

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

相关概念视频

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...